← Eichor
Study identifier: NCT06733246 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Safety and Efficacy Evaluation of the Ceretrieve Device in the Treatment of AIS Patients

Condition: Acute Ischemic Stroke  ·  Sponsor: Ceretrieve Ltd.

PhaseNA
Planned participants132
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The main objective of this clinical trial is to evaluate of the safety \& efficacy of the Ceretrieve device within 24 hours post thrombectomy procedure. This means to assess that the use with the Ceretrieve neuro-thrombectomy device that is designed to treat acute ischemic stroke patients raises no safety concerns and that it is found to be effective when it is used according to its intended purpose, which is revascularization of patients with acute ischemic stroke secondary to intracranial large vessel occlusive disease (involving the internal carotid artery, middle cerebral artery- M1 and M2 segments, basilar, and vertebral arteries). The study researchers will compare the efficacy and safety results of this study to data derived from the literature of FDA approved neuro-thrombectomy devices. The study hypothesis is that The Ceretrieve device would achieve successful reperfusion performance shall be similar to the safety \& performance derived from the literature. The primary outcomes that will be measures are: Performance: Successful reperfusion, defined as core laboratory-adjudicated modified Thrombolysis in Cerebral Ischemia (mTICI) score 2b-3 within three passes of the Ceretrieve system without any rescue. Safety: Symptomatic intra-cranial hemorrhage within 24 (18-36) hours of the study procedure. Patients who will participate in this study will be followed for a time period of 3 months. After discharge from the medical center, they will be asked to arrive to a o…

This description comes directly from the study's public registry record.

Talk to the study team

Hilla Hilla Ben-Ezra, Ms.  ·  +972-52-6511131  ·  hilla@ceretrieve.com

Maysa Mustafa, Ms.  ·  +972-50-2158126  ·  Maysa@ceretrieve.com

Always discuss trial participation with your own doctor first.

Locations (1)

Heidelberg University HospitalHeidelberg, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06733246